Personalized wellness intervention for smoking cessation in adults living with HIV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a 13-week personalized smoking cessation intervention for adults living with HIV who smoke. Participants will be randomly assigned to one of two behavioral health approaches, alongside a standard smoking cessation program that includes varenicline and counseling sessions. The study will assess the impact of these interventions on smoking cessation rates, sleep quality, and cardiovascular health markers. A total of 200 eligible participants will be recruited and monitored throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males and females 18 -75 years;
2. Documented HIV infection;
3. CD4+ T cell count ≥ 200 cells/mm3;
4. On stable antiretroviral therapy without intention of changing, or not on antiretroviral therapy with no immediate intention to start;
5. Smoke at least 5 cigarettes/day;
6. Report wanting to quit smoking in the next month;
7. Have no sleep disorders (with the exception of insomnia or mild to moderate obstructive sleep apnea (STOP-Bang score of 4 or less; apnea-hypopnea index (AHI) of less than 30);
8. Able to communicate in English and provide written informed consent for study procedures;
9. Able to use varenicline tartrate safely;
10. Will be residing in the geographic area for at least 10 months;
11. Willing to attend 8 in-person sessions and one 6-month follow up assessment.

Exclusion Criteria

1. Regular use of chewing tobacco, snuff, cigars, e-cigarettes, unless willing to stop;
2. Current enrollment or plans to enroll in another smoking cessation program or use other smoking cessation products for the duration of the study;
3. Women of childbearing potential who are pregnant, lactating, or likely to become pregnant during the trial and unwilling to use contraception during the study;
4. Unstable alcohol use that precludes reliable study participation as assessed by study physician;
5. Unstable drug use that precludes reliable study participation as assessed by study physician;
6. Unstable mental illness that precludes reliable study participation as assessed by study physician;
7. A history of a suicide attempt within the last two years, and/or current nonspecific suicidal thoughts as defined by the Columbia Suicide Severity Rating Scale;
8. Unstable or untreated moderate or severe depression as assessed by the Patient Health Questionnaire 9 (PHQ-9) scale. A participant with a score of ≥ 15 will be referred to one of the study's mental health clinicians (Dr. Michael Grandner or Dr. Susan Gorovoy) for further assessment of their depression
9. Serious or unstable disease within the past 6 months (e.g., cancer, seizure disorder, end-stage liver disease, end-stage renal disease, uncontrolled diabetes, pulmonary disease requiring oxygen);
10. Any prior history of seizure disorder within the past year;
11. Unstable cardiac condition (i.e., angina, myocardial infarction, or coronary angioplasty) within the past 6 months or a clinically significant EKG that may present a health or safety risk as assessed by the study physician;
12. Currently working night/rotating shift and/or use of a sleep medication, or a medication that could influence sleep;
13. Prior history of adult somnambulism;
14. Use of a sleep medication that will interfere with study results
15. Inability to complete any of the study tasks as determined by the investigators.

Where it's running

• Banner University Medical Center Phoenix
  Phoenix, Arizona, United States Recruiting
• University of Arizona
  Tucson, Arizona, United States Recruiting

Study contacts

• Principal investigator: Elizabeth Connick, MD — University of Arizona
• Study coordinator: Gabriela Montenegro
• Email: mgmonten@arizona.edu
• Phone: (520) 626-7873

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proactive pharmacist e-consults to optimize lung health for people with HIV

  This trial tests whether proactive pharmacist-led e-consults can help people with HIV improve lung-health medications, vaccinations, smoking cessation, and deprescribing of certain inhaled medicines or PPIs.

  Recruiting Seattle Institute for Biomedical and Clinical Research · Boise, Idaho and 2 other locations · NCT07507435

• Quitting Matters: a smoking quit program for people living with HIV

  This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06883097

• Mindfulness and behavior-change program to improve heart health in older adults with HIV

  This project will test a text-message–enhanced mindfulness and behavior-change program to see if it reduces stress and cardiovascular risk in people aged 50+ living with HIV who have elevated psychological distress.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06001814

• Helping Cambodian people with HIV quit smoking using text messages

  This study is testing if sending text messages can help people in Cambodia who have HIV quit smoking by providing support and resources.

  Recruiting at 3 sites H. Lee Moffitt Cancer Center and Research Institute · Phnom Penh and 2 other locations · NCT05746442

• Educational text messages to improve heart health in people with HIV

  This study tests if sending educational text messages can help people over 40 with HIV make better choices for their heart health.

  Recruiting at 2 sites University of California, San Francisco · San Francisco, California and 1 other locations · NCT05642858

• Optimizing smoking cessation treatments for people with HIV in South Africa

  This study is testing a new way to help people with HIV in South Africa quit smoking by using a combination of counseling, support from peers, and medications to see if it works better than what’s currently available.

  Recruiting Phase 2/3 Johns Hopkins University · Soweto, Gauteng · NCT05413122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.